Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Active not recruiting 4

Sponsor Class

NIH 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 1

Conditions

Prostatic Neoplasms 25Breast Neoplasms 19Multiple Myeloma 17Neoplasm Metastasis 15Lung Neoplasms 15Ovarian Neoplasms 14Lymphoma 14Glioma 14Carcinoma, Renal Cell 14Carcinoma, Non-Small-Cell Lung 12Pancreatic Neoplasms 11Fallopian Tube Neoplasms 11Melanoma 10Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 9Sarcoma 9Medulloblastoma 9Cholangiocarcinoma 9Neuroblastoma 8Glioblastoma 8Colonic Neoplasms 8Triple Negative Breast Neoplasms 7Thyroid Neoplasms 7Oropharyngeal Neoplasms 7Uterine Cervical Neoplasms 6Rhabdoid Tumor 6Rectal Neoplasms 6Neuroendocrine Tumors 6Mouth Neoplasms 6Lymphoma, Non-Hodgkin 6

Interventions

Magnetic Resonance Spectroscopy 4Specimen Handling 3Nivolumab 3Biopsy 2dehydroftorafur 1X-Rays 1Watchful Waiting 1Taxes 1Sigmoidoscopy 1Radiotherapy, Intensity-Modulated 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Mitozytrex 1Mitomycin 1Ipilimumab 1Fluorouracil 1Fluorodeoxyglucose F18 1Colonoscopy 1Carboplatin 1Capecitabine 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Anal Canal Carcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04166318 2026-05-05

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
252 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT03403465 2026-02-27

Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers

Duke University

Phase 2 Active not recruiting
90 enrolled
GastrointestinalGynecologic

Anal Canal Carcinoma, Uterine Cervical Neoplasms, Esophageal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡